Pulmotech MAA Market Expected To Grow Steadily And Approach $9.8 Billion By 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Pulmotech MAA Market In 2026 And 2030?

The historical period’s growth was primarily due to a rise in pulmonary embolism instances, the enlargement of hospital-based nuclear medicine units, the accessibility of technetium-derived radiopharmaceuticals, an increase in diagnostic imaging techniques, and enhanced clinical endorsement of lung scintigraphy.

Projected growth during the forecast period stems from the increasing demand for early and precise pulmonary diagnostics, rising investments in nuclear medicine infrastructure, the expansion of clinical research utilizing radiotracers, a growing emphasis on personalized diagnostic imaging, and technological progress in imaging agents. Concurrently, major trends expected in this period encompass the greater adoption of advanced lung perfusion imaging agents, an increased application of nuclear medicine in pulmonary diagnostics, a heightened demand for accurate pulmonary embolism detection, the expansion of radiopharmaceutical clinical uses, and an enhanced focus on imaging accuracy and patient safety.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20329&type=smp

What Key Factors Are Shaping The Pulmotech MAA Market Landscape?

The escalating occurrence of respiratory conditions is projected to boost the pulmotech MAA market. These conditions encompass a wide array of ailments affecting the lungs and other respiratory components like airways and muscles. The rising prevalence of respiratory diseases is influenced by factors such as environmental pollution, lifestyle choices, an aging populace, and enhancements in diagnostic techniques. Pulmotech MAA serves in the diagnosis and management of long-term respiratory issues by facilitating pulmonary imaging to evaluate regional lung function and identify potential anomalies like perfusion deficits. As an illustration, in June 2024, the Australian Institute of Health and Welfare, an Australia-based health and welfare agency, reported that approximately 8.5 million people in Australia, representing 34% of the population, were estimated to be living with chronic respiratory conditions. This figure includes about 2.8 million individuals, or 11% of the population, with asthma, and 638,000 people, or 2.5% of the population, suffering from chronic obstructive pulmonary disease (COPD). Consequently, the increased incidence of respiratory diseases is fueling the pulmotech MAA market. The increasing prevalence of chronic diseases is set to drive the expansion of the pulmotech MAA market. Chronic diseases are defined as health conditions that persist for prolonged periods, often spanning years or a lifetime. This rise in chronic diseases is primarily attributed to shifts in lifestyle, an aging global population, and environmental factors. Pulmotech MAA offers significant utility in managing the escalating burden of chronic diseases, particularly those impacting the respiratory system. It is employed in the assessment and treatment of these conditions by enabling precise imaging of pulmonary perfusion, assisting in the diagnosis of ailments such as pulmonary embolism, and monitoring various lung disorders. For instance, in April 2025, the National Center for Health Statistics (NCHS) under the Centers for Disease Control and Prevention (CDC), a US-based source of health statistics, highlighted an upward trend in chronic diseases, notably among young and midlife adults. Among young adults, obesity prevalence saw an increase from 27.3% in 2023, and depression rose from 25.0%, alongside noted increases in diabetes and chronic kidney disease in midlife adults. Thus, the growing prevalence of chronic diseases is anticipated to spur the growth of the pulmotech MAA market.

Which Segments Define The Pulmotech MAA Market Segment Structure?

The pulmotech maa market covered in this report is segmented –

1) By Application: Pulmonary Embolism Diagnosis, Preoperative Assessment, Lung Transplant Viability, Chronic Respiratory Disease Evaluation, Clinical Research

2) By Distribution Channel: Direct Sales, Distributors, Online Platforms

3) By End-User: Hospitals, Research Institutions, Diagnostic Imaging Centers

Who Are The Established Players Within The Pulmotech MAA Market?

Major companies operating in the pulmotech maa market are Curium Pharma

Get The Full Pulmotech MAA Market Report:

https://www.thebusinessresearchcompany.com/report/pulmotech-maa-global-market-report

Which Region Represents The Largest Share Of The Pulmotech MAA Market?

North America was the largest region in the pulmotech MAA market in 2025. The regions covered in the pulmotech maa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pulmotech MAA Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pulmotech-maa-global-market-report

Browse Through More Reports Similar to the Global Pulmotech MAA Market 2026, By The Business Research Company

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Consumer Iam Market Report 2026

https://www.thebusinessresearchcompany.com/report/consumer-iam-global-market-report

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795